Article in Microbiology spectrum, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
5 citing papers in PubMed, 7 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors at 7 institutions in 3 countries.
Aitor Nogales *Department of Microbiology and Immunology, School of Medicine and Dentistry, University of Rochestergrid.16416.34, Rochester, New York, USA.ORCID 0000-0002-2424-7900
John Steel *Department of Microbiology and Immunology, Emory University School of Medicinegrid.471395.d, Atlanta, Georgia, USA.
Wen-Chun Liu *Department of Microbiology, Icahn School of Medicine at Mount Sinaigrid.59734.3c, New York, New York, USA.
Anice C LowenDepartment of Microbiology and Immunology, Emory University School of Medicinegrid.471395.d, Atlanta, Georgia, USA.ORCID 0000-0002-9829-112X
Laura RodriguezDepartment of Microbiology and Immunology, School of Medicine and Dentistry, University of Rochestergrid.16416.34, Rochester, New York, USA.
Kevin ChiemDepartment of Microbiology and Immunology, School of Medicine and Dentistry, University of Rochestergrid.16416.34, Rochester, New York, USA.
Andrew CoxDepartment of Microbiology and Immunology, School of Medicine and Dentistry, University of Rochestergrid.16416.34, Rochester, New York, USA.
Adolfo García-SastreDepartment of Microbiology, Icahn School of Medicine at Mount Sinaigrid.59734.3c, New York, New York, USA.ORCID 0000-0002-6551-1827
Randy A AlbrechtDepartment of Microbiology, Icahn School of Medicine at Mount Sinaigrid.59734.3c, New York, New York, USA.ORCID 0000-0003-4008-503X
Stephen DewhurstDepartment of Microbiology and Immunology, School of Medicine and Dentistry, University of Rochestergrid.16416.34, Rochester, New York, USA.
Luis Martínez-SobridoDepartment of Microbiology and Immunology, School of Medicine and Dentistry, University of Rochestergrid.16416.34, Rochester, New York, USA.ORCID 0000-0001-7084-0804
Emory University · USIcahn School of Medicine at Mount Sinai · USTexas Biomedical Research Institute · USUniversity of Rochester · USAcademia Sinica · TWAgencia Española de Medicamentos y Productos Sanitarios · ESInstituto Nacional de Investigación y Tecnología Agraria y Alimentaria · ES
Funding
COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTER: UNIVERSAL INFLUENZA VACCINE RESEARCH75N93019C00051 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KRAMMER, FLORIAN · 2019 to 2025
$105.4M
NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities75N93021C00014 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GARCIA-SASTRE, ADOLFO · 2021 to 2025
$62.6M
Pediatric Scientist Development Program (PSDP) [K12]K12HD000850 · NICHD · YALE UNIVERSITY · PI Sallie R. Permar · 1987 to 2026
$44.1M
Toward a Universal Influenza Virus VaccineP01AI097092 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI PALESE, PETER · 2012 to 2022
$17.6M
University of Rochester Mentoring Environment: Nurturing Training Opportunities in Research (UR-MENTOR)T32GM007356 · NIGMS · UNIVERSITY OF ROCHESTER · PI O'BANION, M. KERRY · 1985 to 2023
$15.1M
The T32 Predoctoral Training Program in Immunology (PTPI)T32AI007285 · NIAID · UNIVERSITY OF ROCHESTER · PI Scott Andrew Gerber, JACQUES Robert · 1986 to 2026
$7.6M
Medical Scientist Training ProgramT32GM063483 · NIGMS · UNIVERSITY OF CINCINNATI · PI KHURANA HERSHEY, GURJIT K. · 2002 to 2022
$6.7M
Training in Cellular, Biochemical and Molecular SciencesT32GM068411 · NIGMS · UNIVERSITY OF ROCHESTER · PI MAQUAT, LYNNE E · 2005 to 2019
$3.9M
Dynamics of the protective vaccine-induced human influenza neuraminidase B cell responseR01AI145332 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KOBIE, JAMES J, MARTINEZ-SOBRIDO, LUIS · 2019 to 2022
$3.0M
Infection and Immunity: The Pathogenesis of Host-Microbe InteractionsT32AI118689 · NIAID · UNIVERSITY OF ROCHESTER · PI Paul M. Dunman, BRIAN M WARD · 2015 to 2026
$2.5M
Pathogenesis and therapeutic targeting of immune disordersT32AI118697 · NIAID · CINCINNATI CHILDRENS HOSP MED CTR · PI HILDEMAN, DAVID A · 2016 to 2020
$683k
Enhanced Live Attenuated Influenza Virus With Improved Safety and ImmunogenicityR21AI112717 · NIAID · UNIVERSITY OF ROCHESTER · PI DEWHURST, STEPHEN · 2014 to 2015
Influenza A viruses (IAV) remain emerging threats to human public health. Live-attenuated influenza vaccines (LAIV) are one of the most effective prophylactic options to prevent disease caused by influenza infections. However, licensed LAIV remain restricted for use in 2- to 49-year-old healthy and nonpregnant people. Therefore, development of LAIV with increased safety, immunogenicity, and protective efficacy is highly desired. The U.S.-licensed LAIV is based on the master donor virus (MDV) A/Ann Arbor/6/60 H2N2 backbone, which was generated by adaptation of the virus to growth at low temperatures. Introducing the genetic signature of the U.S. MDV into the backbone of other IAV strains resulted in varying levels of attenuation. While the U.S. MDV mutations conferred an attenuated phenotype to other IAV strains, the same amino acid changes did not significantly attenuate the pandemic A/California/04/09 H1N1 (pH1N1) strain. To attenuate pH1N1, we replaced the conserved leucine at position 319 with glutamine (L319Q) in PB1 and analyzed the
Indexed as
Influenza A virusInfluenza A Virus, H1N1 SubtypeInfluenza, HumanInfluenza VaccinesOrthomyxoviridae InfectionsAnimalsFerretsGuinea PigsHumansMutationVaccines, AttenuatedViral ProteinsInfluenza Vaccinesinfluenza virus polymerase basic protein 1Vaccines, AttenuatedViral Proteinsattenuatedcold-adaptedferretsguinea pigsinfluenza A viruslive-attenuated influenza vaccinesmaster donor virusprotection efficacytemperature sensitivetransmissionvaccines
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Mutation L319Q in the PB1 Polymerase Subunit Improves Attenuation of a Candidate Live-Attenuated Influenza A Virus Vaccine. · full record | OpenQuestion